EBS Stock Analysis: Buy, Sell, or Hold?
EBS - Emergent Biosolutions, Inc.
$4.84
-0.47 (-8.85%)
▼
5d:
-32.96%
30d:
-40.83%
90d:
-46.99%
WAIT
LOW Confidence
Analysis Updated: Aug 7, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When EBS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: EBS is down 33.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: EBS is down 33.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$11.93
Based on -0.1% avg growth
INTRINSIC VALUE TODAY
$7.41
34.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EBS is currently trading at $4.84, which is considered oversold relative to its 30-day fair value range of $6.80 to $8.36. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.3) compared to its historical average (13.2). Remarkably, the market is currently pricing in an annual earnings decline of 26.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EBS is in a downtrend. The price is currently testing key support at $4.81. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.9% recently.
Market Sentiment: EBS scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+147.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EBS is in a downtrend. The price is currently testing key support at $4.81. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.9% recently.
Market Sentiment: EBS scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+147.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.80 -
$8.36
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
Protect Your Profits
Holding EBS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.9%)
- BULLISH: Trading 147.9% below Wall St target ($12.00)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.80 -
$8.36
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.81
Resistance Level
$7.70
Current Trend
Downtrend
Technical data as of
Aug 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.32
Wall Street Target
$12.00
(+147.9%)
Revenue Growth (YoY)
-29.7%
Earnings Growth (YoY)
-93.8%
Profit Margin
-1.3%
Valuation Discount vs History
-26.2% cheaper
PE vs Historical
5.3 vs 13.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-26.2%
(market-implied from PE analysis)
1-Year Target
$4.36
(-10%)
2-Year Target
$3.92
(-19%)
3-Year Target
$3.53
(-27%)
3-Yr Target (if PE normalizes)
(PE: 5→13)
$8.76
(+81%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: -4.2%)
$16.18
(+234%)
Base:
(SPY PE: 5.3, Growth: -4.2%)
$4.25
(-12%)
Bear:
(PE: 4.5, Growth: -4.2%)
$3.62
(-25%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.3 to 13.2
Stabilization Target:
$12.01
(+148.2%)
PE Expansion Potential:
+148.2%
Share & Embed Analysis
Last updated: August 10, 2026 1:10 AM ET
Data refreshes hourly during market hours. Next update: 2:10 AM
Data refreshes hourly during market hours. Next update: 2:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EBS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$213 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$658 | 59 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$108 | 47 HOLD |
Advanced EBS Option Strategies
Professional options setups generated by AI based on today's EBS price and gamma walls.
